MedTrace Logo

HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598

NCT00896909 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2017-05-17

No results posted yet for this study

Summary

RATIONALE: Collecting samples of tumor tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at HER-2 mutations in tumor samples from patients with advanced non-small cell lung cancer being treated with trastuzumab on clinical trial ECOG-2598.

Conditions

Interventions

GENETIC

gene expression analysis

GENETIC

mutation analysis

GENETIC

polymerase chain reaction

OTHER

diagnostic laboratory biomarker analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • ECOG-ACRIN Cancer Research Group

    lead NETWORK

Principal Investigators

  • David P. Carbone, MD, PhD · Vanderbilt-Ingram Cancer Center

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-02
Primary Completion
2006-07-02
Completion
2006-07-02

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00896909 on ClinicalTrials.gov